One group tested a tandem bispecific CAR T therapy targeting both BCMA and CD38 linked to 4-1BB and CD3ζ costimulatory domains as part of a phase 1 trial to assess efficacy, durability, and safety profiles in the R/R multiple myeloma setting. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.